window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : March 11, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Takeda

  • Artificial Intelligence,Cell & Gene Therapy,Drug Development,Research & Development,Technology and platforms

    AISB Network expands Federated OpenFold3 initiative with three new pharma contributors

    The AI Structural Biology (AISB) Network, powered by Apheris GmbH, [...]

    September 23, 2025
  • Biologics & Biosimilars,Clinical Development,Drug Development,Rare Diseases

    Takeda’s mezagitamab shows rapid, durable platelet response in Phase 2 ITP trial

    Data presented at ISTH 2025 highlight potential for improved outcomes [...]

    July 3, 2025
  • Clinical Trials,Drug Development

    EC approves ADCETRIS-based BrECADD regimen for newly diagnosed advanced Hodgkin lymphoma

    Takeda’s antibody-drug conjugate gains second frontline indication following positive Phase [...]

    June 23, 2025
  • Biologics & Biosimilars,Precision medicine,Regulatory Affairs

    Protagonist and Takeda present VERIFY data on rusfertide showing strong results in polycythemia vera

    Protagonist and Takeda have shared full 32-week results from the [...]

    June 2, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  •
    ViiV Healthcare reports 12-month data showing lotivibart maintains viral suppression in ultra long-acting HIV regimen
    Categories: Clinical Development, Infectious Diseases, Patient Centricity, Precision medicine
  • SPT Labtech and Illumina to develop automated platform for decentralised oncology genomics
    Categories: Diagnostics, Oncology, Partnerships & Funding
  • Young adults in US, UK and Australia hit hardest by global mental health decline
    Categories: Clinical studies, Digital Health, Global health, Mental health, Neurosciences
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top